Synopsis: Pharma stock fell 9 percent despite reporting Rs 180 crore Q1 revenue and 56 percent YoY profit growth, as investor sentiment may have been affected by weaker sequential earnings.
The share of this company, which specializes in complex generics, active pharmaceutical ingredients (APIs), and specialty therapeutic solutions, gained investor traction after posting mixed Q1 results
With a market capitalization of Rs 6,120 crore, Senores Pharmaceuticals Ltd’s share on Tuesday made a day low of Rs 1,288.70 per share, down by 8.7 percent from its previous day’s close price of 1,411.50 per share. The share of the company gave a return of 106 percent over the last year.
Result Overview
QoQ Performance
Revenue grew by 2.86 percent to Rs 180 crore in Q1 FY27 from Rs 175 crore in Q4 FY26, and EBITDA grew by 13.26 percent to Rs 53.8 crore in Q1 FY27 from Rs 47.5 crore in Q4 FY26. Accompanied by a net profit decrease of 17.17 percent to Rs 30.4 crore in Q1 FY27 from Rs 36.7 crore in Q4 FY26, resulting in an EPS decrease of 2.77 percent to Rs 6.67 per share in Q1 FY27 from Rs 6.86 per share in Q4 FY26.
YoY Performance
Revenue grew by 31 percent YoY to Rs 180 crore in Q1 FY27 (Jun 2026) from Rs 138 crore in Q1 FY26 (Jun 2025), and EBITDA grew by 57 percent to Rs 53.8 crore in Q1 FY27 from Rs 34.2 crore in Q1 FY26. Accompanied by a net profit growth of 56 percent to Rs 30.4 crore in Q1 FY27 from Rs 21.2 crore in Q1 FY26, resulting in an EPS growth of 56 percent to Rs 6.67 per share in Q1 FY27 from Rs 4.28 per share in Q1 FY26.
Segment-wise performance
The company’s Regulated Markets remained its largest business segment in Q1 FY27, generating revenue of Rs 127.8 crore, up 41.9 percent YoY from Rs 90.1 crore. The Emerging Markets business also posted healthy growth, with revenue rising 29.6 percent YoY to Rs 37.6 crore from Rs 29 crore.
The Branded Generics segment remained under pressure, with revenue declining 2.4 percent YoY to Rs 8 crore from Rs 8.2 crore. Meanwhile, the Others segment, which includes API sales, reported revenue of Rs 6.8 crore, up 29.2 percent YoY from Rs 5.2 crore.
Overall, the company’s total revenue increased 35.9 percent YoY to Rs 180.2 crore in Q1 FY27 from Rs 132.6 crore in the same quarter last year, supported mainly by strong growth in its regulated and emerging markets businesses.
Key Concerns in Q1 FY27
Revenue and profit decline sequentially
The company reported a sequential decline in its financial performance during Q1 FY27. Muted Revenue growth to Rs 180.2 crore from Rs 175 crore in Q4 FY26, while net profit declined to Rs 30.7 crore from Rs 37 crore. The results also came in below market expectations for quarter-on-quarter growth.
Branded Generics business remained under pressure
The Branded Generics business continued to see weak performance during the quarter. Revenue from the segment declined 2.4 percent YoY to Rs 8 crore, despite the company expanding its product portfolio and increasing its field force.
Lower other income limited profit growth
The company’s other income dropped sharply during the quarter. It fell 67.8 percent YoY to Rs 2.8 crore from Rs 8.7 crore in the same period last year, limiting growth in profit before tax despite a strong operating performance.
Higher costs put pressure on margins
Operating costs increased at a faster pace than revenue during Q1 FY27. Employee expenses rose 37.8 percent YoY, while other expenses increased 48.1 percent YoY, putting pressure on the company’s overall profitability and margins.
Emerging markets affected overall margins
The company’s emerging markets business reported an EBITDA margin of around 14 percent, much lower than the 40 percent margin earned in regulated markets. Since emerging markets contributed 21 percent of total revenue, the lower margins weighed on the company’s overall profitability.
Conclusion
Investor sentiment may have been impacted despite the company’s strong YoY growth in revenue and profit, as the market focused on the sequential decline in revenue and net profit, pressure on margins from higher operating costs, weaker Branded Generics performance, and lower other income.
About the Company
Incorporated in 2015, Senores Pharmaceuticals Ltd is a global, research-driven pharmaceutical company headquartered in Ahmedabad, India, specializing in complex generics, active pharmaceutical ingredients (APIs), and specialty therapeutic solutions. It operates across regulated and emerging markets, including the US, Canada, and the UK.
Senores has taken a major step to expand its presence in the US by forming a 70 percent joint venture called Amerisyn. The partnership gives the company direct access to the US federal pharmaceutical market, including government agencies, the US military, and Veterans Affairs, creating a new long-term growth opportunity.
The US government drug procurement market has high entry barriers due to strict regulations, long-term contracts, and specialized procurement processes. Through Amerisyn and its experienced partners, Senores aims to secure federal contracts while strengthening its broader US business with manufacturing, approved products, commercialization capabilities, and wider market access.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
